(Q44048395)

English

Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

scientific article published on 26 August 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

12

object named as

Eric P Winer

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

9

object named as

Nancy Lin

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Clifford A Hudis

14

object named as

Clifford A Hudis

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Alyson Abbruzzi

5

object named as

Alyson Abbruzzi

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Richard Steingart

7

object named as

Richard Steingart

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Patrick G Morris

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Neil M Iyengar

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sujata Patil

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Carol Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Robert Lehman

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kevin C Oeffinger

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Beverley Moy

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Steven E Come

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Chau T Dang

15

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

26 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3943-3951

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

21 January 2018

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

7 January 2021

based on heuristic

inferred from DOI database lookup

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

7 January 2021

based on heuristic

inferred from DOI database lookup

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28284

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28284

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44048395&oldid=2117187574"